SMAD4 as a Prognostic Marker in Colorectal Cancer

More than 50% of patients with Dukes C colorectal cancer have disease recurrence and die within 5 years after surgical removal of their primary tumor. It is currently not possible to distinguish patients with good and bad prognosis. SMAD4 is an important tumor suppressor gene that mediates transforming growth factor-β superfamily signaling and is located in chromosome 18q21, a region with frequent genetic losses in these tumors. Allelic imbalance in 18q has been linked to poor prognosis in a subset of colorectal cancer patients. Therefore, we generated a tissue microarray containing triplicate tumor samples from 86 Dukes C patients and used immunohistochemistry to assess the relative expression level of SMAD4 and its value as a prognostic marker. In addition, SMAD4 was screened for mutations and two polymorphic microsatellite markers were used to assess the presence of allelic imbalance in these tumors. Patients with tumors expressing high SMAD4 levels had significantly better overall (P < 0.025) and disease-free (P < 0.013) survival than patients with low levels. This identifies SMAD4 as a prognostic marker for Dukes C colorectal cancer. Although all tumors with absent SMAD4 staining showed allelic imbalance in 18q21, tumors with 18q21 allelic imbalance as a group showed no difference in SMAD4 levels compared with tumors without allelic imbalance, suggesting that additional mechanisms of SMAD4 down-regulation exist. In addition, although SMAD4 mutations were found in five tumors, they were not associated with shorter survival. In conclusion, the level of expression of SMAD4 was found to be a more sensitive marker than 18q21 allelic imbalance and SMAD4 mutations, which were of no prognostic significance for these patients.

[1]  L. Aaltonen,et al.  SMAD genes in juvenile polyposis , 1999, Genes, chromosomes & cancer.

[2]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[3]  G. Taylor,et al.  Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. , 1993, Gastroenterology.

[4]  L. Aaltonen,et al.  Mutations in the SMAD4/DPC4 gene in juvenile polyposis. , 1998, Science.

[5]  Smads and early developmental signaling by the TGFbeta superfamily. , 1998, Genes & development.

[6]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[7]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[8]  M. Emi,et al.  Inactivation of both alleles of the DPC4/SMAD4 gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumors from Japanese patients. , 1999, Mutation research.

[9]  J. Benhattar,et al.  Prognostic significance of K-ras mutations in colorectal carcinoma. , 1993, Gastroenterology.

[10]  L. Aaltonen,et al.  Semiautomated assessment of loss of heterozygosity and replication error in tumors. , 1996, Cancer research.

[11]  J. Fleshman,et al.  Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Lothe,et al.  Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Whitman.  Smads and early developmental signaling by the TGFbeta superfamily. , 1998, Genes & development.

[14]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[15]  Irene L Andrulis,et al.  MADR2 Maps to 18q21 and Encodes a TGFβ–Regulated MAD–Related Protein That Is Functionally Mutated in Colorectal Carcinoma , 1996, Cell.

[16]  E. Stone,et al.  A gene for familial juvenile polyposis maps to chromosome 18q21.1. , 1998, American journal of human genetics.

[17]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[18]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[19]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Vihko,et al.  Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers , 1999, British Journal of Cancer.

[21]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[22]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[23]  R. Gafà,et al.  Chromosome 18q allelic loss and prognosis in stage II and III colon cancer , 1998, International journal of cancer.

[24]  D. Smith,et al.  p53 point mutation and survival in colorectal cancer patients. , 1995, Cancer research.

[25]  Z. F. Liu,et al.  Allelic loss of chromosome 18q and prognosis in colorectal cancer. , 1994, The New England journal of medicine.

[26]  L. Myeroff,et al.  A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-beta independence without inactivating the p53 tumor suppressor gene. , 1994, The Journal of clinical investigation.

[27]  L. Aaltonen,et al.  Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). , 2001, Cancer research.

[28]  Scott E. Kern,et al.  Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.

[29]  Hiroyuki Miyoshi,et al.  Intestinal Tumorigenesis in Compound Mutant Mice of both Dpc4(Smad4) and Apc Genes , 1998, Cell.

[30]  J. Eshleman,et al.  Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. , 1995, Cancer research.

[31]  L. Aaltonen,et al.  Allelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC. , 2001, The American journal of pathology.

[32]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[33]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Sparks,et al.  Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation , 2000 .

[35]  O. Delattre,et al.  Survival and acquired genetic alterations in colorectal cancer. , 1992, Gastroenterology.

[36]  Kathleen R. Cho,et al.  Identification of a chromosome 18q gene that is altered in colorectal cancers. , 1990, Science.

[37]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[38]  S. Markowitz.  TGF-beta receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis. , 2000, Biochimica et biophysica acta.

[39]  K. Cohn,et al.  The significance of allelic deletions and aneuploidy in colorectal carcinoma , 1997, Cancer.

[40]  C. Tangen,et al.  Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report , 1995, Annals of Internal Medicine.

[41]  A. Munakata,et al.  KAI1, CAR, and Smad4 expression in the progression of colorectal tumor , 2001, Journal of Gastroenterology.

[42]  L. Aaltonen,et al.  Frequent loss of SMAD4/DPC4 protein in colorectal cancers , 2002 .

[43]  B. Johansson,et al.  A breakpoint map of recurrent chromosomal rearrangements in human neoplasia , 1997, Nature Genetics.

[44]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[45]  L. Aaltonen,et al.  Frequent loss of SMAD4/DPC4 protein in colorectal cancers , 2002, Gut.

[46]  L. Aaltonen,et al.  No SMAD4 hypermethylation in colorectal cancer , 2000, British Journal of Cancer.